KRP-105

• Description :

  KRP-105 is a potent, highly selective, and orally effective PPAR alpha (EC50 = 8 nM) agonist. KRP-105 can significantly reduce serum triglyceride, total cholesterol, and non high density lipoprotein cholesterol levels. KRP-105 can be used for research on metabolic diseases such as dyslipidemia[1].

• UNSPSC :

  12352005

• Target :

  PPAR

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Field of Research :

  Metabolic Disease

• Smiles :

  OC(C1=CC=CC(N(CCC2)C[C@H]2NC(C3=C(C)N=C(C4=CC=C(C=C4)Cl)S3)=O)=C1)=O

• Molecular Formula :

  C23H22ClN3O3S

• Molecular Weight :

  455.96

• References & Citations :

  [1]Nomura M, et al. Discovery of cyclic amine-substituted benzoic acids as PPARα agonists. Bioorg Med Chem Lett. 2012 Jan 1;22 (1) :334-8.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PPARα

• CAS Number :

  [876145-69-6]